Adagio Medical Holdings, Inc

Adagio Medical Holdings, Inc

NNASDAQ:ADGM
1.61
USD
-0.32
(-16.58%)
-40.73EPS
14.47MMarket Cap
Apr 05Next Earn
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.61
0.42
0.67
- -
- -
- -
Basic EPS, GAAP
-44.68
-53.05
-85.48
- -
-45.45
-40.73
Free Cash Flow per Basic Share
-46.11
-51.35
-58.24
- -
-35.13
-24.87
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
-162.73
-214.85
-272.49
39.3
16.75
-0.56
Tangible Book Value per Share
-162.73
-214.85
-272.49
-2.02
-11.53
-28.84
Basic Weighted Avg Shares
- -
- -
- -
1
1
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-7,646.3
-12,652.38
-9,314
- -
- -
- -
Depreciation Expense
- -
- -
1
- -
1
1
Net Income, GAAP
-20
-24
-38
- -
-25
-27
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-7,384.44
-12,525.4
-12,715.33
- -
- -
- -
Working Capital
17
-6
-42
18
12
3
LT Debt
- -
- -
- -
16
22
26
Total Equity
-73
-96
-132
20
12
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-155.25
- -

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
21
23
25
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
23
26
14

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
20
16
11
Cash, Cash Equivalents & STI
17
13
8
Accounts Receivable, Net
- -
- -
- -
Inventories
2
2
2
Total Current Liabilities
8
9
8
Payables & Accruals
7
6
5
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-37.72%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-17.97
-12.85
- -
- -
- -
2025
-15.05
-7.7
-19.73
-4.92
-45.45
2026
-9.45
-9.07
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Todd Usen
Full Time Employees
41
Sector
Health technology
Industry
Medical specialties
Address
26051 Merit Circle Laguna Hills CA United States 92653
IPO Date
Aug 1, 2024
Business
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) develops and commercializes innovative ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company offers a portfolio of ultra-low temperature cryoablation (ULTC) and pulsed field cryoablation (PFCA) systems; iCLAS atrial ULTC catheter and accessories for paroxysmal atrial fibrillation, persistent atrial fibrillation, and atrial flutter, with CE mark in the European Union; vCLAS ventricular ULTC catheter designed for ventricular arrhythmias; Cryopulse atrial PFCA catheter and accessories; and a shared ULTC cryoablation console across its catheter families. Founded in 2011 and headquartered in Laguna Hills, California, Adagio Medical Holdings operates primarily in the United States and European Union markets, targeting electrophysiologists and healthcare providers treating patients with drug-resistant arrhythmias. In July 2024, the company completed a business combination with ARYA Sciences Acquisition Corp IV, listing on Nasdaq under the ADGM ticker and raising approximately $84.2 million in financing from investors including affiliates of Perceptive Advisors, RA Capital Management, RTW Investments, and ATW Partners. In October 2025, Adagio Medical Holdings closed a private placement providing up to $50 million in gross proceeds, including $19 million upfront led by Perceptive Advisors and other healthcare-focused investors, to fund FDA submission for the vCLAS ULTC System via the FULCRUM-VT pivotal study, next-generation catheter development, manufacturing expansion, and commercial readiness. The company completed enrollment in the 209-patient FULCRUM-VT US IDE trial in third quarter 2025, reporting 97% acute effectiveness and a favorable safety profile, alongside securing FDA Breakthrough Device Designation, CMS Category B coverage, and leadership additions including Deborah Kaster as Chief Financial Officer.

Company News

  • Adagio Medical Reports Third Quarter 2026 Results

  • Adagio Medical Provides Business Update: 22 Patients Treated with Next-Generation vCLAS™ Ultra System as FULCRUM-VT IDE Sub-Study Advances

  • Adagio Medical Holdings, Inc. (NASDAQ:ADGM) Sees Significant Growth in Short Interest

  • Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value

  • Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner -- University Medical Center Phoenix

  • Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner – University Medical Center Phoenix

  • Adagio Medical Reports Second Quarter 2026 Results

  • Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

  • Robo.ai Announces Core Executive Appointments, Forming a Local UAE Leadership Team at Neurovia AI

  • Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia

  • Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress

  • Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference

  • Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System

  • Adagio Medical Holdings, Inc. (NASDAQ:ADGM) Sees Large Growth in Short Interest

  • Sensus Healthcare (NASDAQ:SRTS) versus Adagio Medical (NASDAQ:ADGM) Head to Head Contrast

  • Adagio Medical's ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference

  • Short Interest in Adagio Medical Holdings, Inc. (NASDAQ:ADGM) Rises By 60.0%

  • Adagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS® Ventricular Ablation System

  • Adagio Medical to Participate in the 25th Annual Needham Virtual Conference

  • Adagio Medical Ultralow Temperature Ablation U.S. Pivotal Study Results to be Presented in Late-Breaking Session at Heart Rhythm Society 2026